Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Kite Pharma, Inc. (KITE) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2017 8-K Quarterly results
09/25/2017 8-K Quarterly results
09/05/2017 8-K Quarterly results
08/28/2017 8-K Quarterly results
08/08/2017 8-K Quarterly results
Docs: "Kite Reports Second Quarter 2017 Financial Results"
06/23/2017 8-K Form 8-K - Current report
05/08/2017 8-K Form 8-K - Current report
04/12/2017 8-K Form 8-K - Current report
03/16/2017 8-K Form 8-K - Current report
03/06/2017 8-K Form 8-K - Current report
02/28/2017 8-K Form 8-K - Current report
01/10/2017 8-K Form 8-K - Current report
01/09/2017 8-K Form 8-K - Current report
01/05/2017 8-K Form 8-K - Current report
12/27/2016 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
09/26/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Kite Pharma Announces Positive Topline KTE-C19 Data from ZUMA-1 Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphoma"
08/08/2016 8-K Form 8-K - Current report
07/06/2016 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Standard Industrial Commercial Multi-Tenant Lease by and between Kite Pharma, Inc. and 2383 Utah, LLC"
06/06/2016 8-K Form 8-K - Current report
06/02/2016 8-K Form 8-K - Current report
05/16/2016 8-K Form 8-K - Current report
05/09/2016 8-K Quarterly results
Docs: "Kite Pharma Reports First Quarter 2016 Financial Results"
02/29/2016 8-K Quarterly results
Docs: "Kite Pharma Reports Fourth Quarter and Full-Year 2015 Financial Results"
12/22/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/10/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and between Kite Pharma, Inc. and Jefferies LLC and Citigroup Global Markets Inc., as representatives for the several underwriters",
"Opinion of Cooley LLP"
12/08/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Updated Company Disclosure"
12/07/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Kite Pharma Presents Phase 1 Results from ZUMA-1 at the 57th American Society of Hematology Annual Meeting"
11/12/2015 8-K Quarterly results
Docs: "Kite Pharma Reports Third Quarter 2015 Financial Results and Provides Business Update Santa Monica, Calif., November 12, 2015 - Kite Pharma, Inc. , a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy products for the treatment of cancer, today reported financial results for the quarter ended September 30, 2015. “Over the past few months, we have achieved many significant corporate and clinical development milestones, including the initiation of two pivotal Phase 2 studies of our lead product candidate, KTE-C19,” noted Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer. “Our ZUMA-1 trial is enrolling patients with aggressive, refractory non-Hodgkin's lymphoma, while our ZUMA-2 trial is enrolling patients with relap..."
11/05/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Kite Pharma to Present Four Abstracts, including Safety and Efficacy Data from the KTE-C19 Phase 1study in Patients with Refractory, Aggressive NHL , at the 57th American Society of Hematology Annual Meeting"
10/27/2015 8-K Entry into a Material Definitive Agreement
10/20/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor -Based Products to Treat Tumors Expressing MAGE SANTA MONICA, Calif., Oct. 20, 2015 — Kite Pharma, Inc. , a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health for intellectual property related to T Cell Receptor -based product candidates directed against MAGE A3 and A3/A6 antigens for the treatment of tumors expressing MAGE, which include lung, pancreatic, gastric, and breast cancers, among others. The National Cancer Institute , with Dr. Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery..."
09/15/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Franz B. Humer, Former Chairman and CEO of Roche Group, Appointed to Kite Pharma's Board of Directors"
08/17/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Kite Pharma Provides Update on KTE-C19 Clinical Trial"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy